Think of Sulfonylureas as CV Neutral

December 2019

New evidence will provide more reassurance about the cardiovascular safety of sulfonylureas (glimepiride, etc) for type 2 diabetes.

There's been debate for years over whether sulfonylureas increase CV risk...mainly due to data with the old, first-generation tolbutamide.

To date, all sulfonylurea med labels warn of increased CV mortality.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote